Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Danaher Corporation (DHR) vs Palantir Technologies Inc (PLTR) Price & Performance

Danaher CorporationTrade
Palantir Technologies IncTrade

Price performance (Past 24H)

Key statistics

Danaher Corporation vs Palantir Technologies Inc — how do they compare? Danaher Corporation trades at $207.4 (market cap $147.18B), while Palantir Technologies Inc trades at $172.95 (market cap $421.09B). The key difference: Palantir Technologies Inc is far larger — about 2.9× Danaher Corporation's market cap, and Danaher Corporation pays a 0.76% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.

DHRPLTR
Market Cap
$147.18B$421.09B
Sector
HealthTechnology
52-Week High
$242.05$207.18
52-Week Low
$161.91$107.27
Enterprise Value
$169.39B$411.89B
Dividend Yield
0.76%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Danaher Corporation

Danaher (DHR) trades at $207.44, up 1.31% today, near its pivot point of $207. The stock exhibits a bullish technical trend, supported by moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company maintains strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights the acquisition of Masimo and new product launches from its SCIEX unit, signaling growth initiatives.

The outlook remains positive with analyst consensus favoring a Buy rating and a $202.33 price target, though the current price exceeds this. Risks include a high P/E ratio of 37.32 and ongoing legal settlements, but robust cash flow and institutional accumulation provide support. Earnings growth in the biotechnology segment is a key catalyst for further upside.

Palantir Technologies Inc

Palantir (PLTR) trades at $172.01, up 10.32% in 24 hours and near its 52-week high, with bullish technical signals from moving averages. The company reported strong Q2 2026 earnings, beating estimates with 93% revenue growth and a 55% net income margin, while raising full-year guidance. Analyst consensus is a Buy with a $213.44 price target, reflecting optimism around AI-driven commercial expansion.

Outlook remains positive due to accelerating revenue and robust profitability, but high valuation multiples (P/E of 147.02) pose a risk if growth slows. Key opportunities include the $13.1 billion deal backlog and U.S. commercial segment growth, while risks involve competition and execution challenges in sustaining AI adoption momentum.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Danaher Corporation

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.

Read more on DHR

About Palantir Technologies Inc

Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.

Read more on PLTR